EGFR Inhibitors for Neoadjuvant and Adjuvant Therapy of NSCLC
<p>5-year survival rates of Non-Small Cell Lung Cancer (NSCLC) remain unsatisfactory after surgery with curative intent and disease recurrences, including distant metastases, are frequent. Only a minority of this heterogeneous disease is positive for EGFR mutations and suitable for Tyrosine Ki...
Saved in:
Main Author: | |
---|---|
Format: | Book |
Published: |
Journal of Surgery and Surgical Research - Peertechz Publications,
2015-12-17.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
LEADER | 00000 am a22000003u 4500 | ||
---|---|---|---|
001 | peertech__10_17352_2455-2968_000019 | ||
042 | |a dc | ||
100 | 1 | 0 | |a Fabio Villa |e author |
245 | 0 | 0 | |a EGFR Inhibitors for Neoadjuvant and Adjuvant Therapy of NSCLC |
260 | |b Journal of Surgery and Surgical Research - Peertechz Publications, |c 2015-12-17. | ||
520 | |a <p>5-year survival rates of Non-Small Cell Lung Cancer (NSCLC) remain unsatisfactory after surgery with curative intent and disease recurrences, including distant metastases, are frequent. Only a minority of this heterogeneous disease is positive for EGFR mutations and suitable for Tyrosine Kinase-Inhibitor biological agents, which however present limits in terms of stable response to treatment, due to the acquired drug resistances. A few trials administrating EGFR inhibitors combined with surgery, in neoadjuvant or adjuvant settings, have been reported with lack of evidence. The third-generation EGFR inhibitors, with the amelioration of techniques of gene profiling and the knowledge of pathways could extent the spectrum of complementary-to-surgery treatments in NSCLC at high risk of relapse.</p> | ||
540 | |a Copyright © Fabio Villa et al. | ||
546 | |a en | ||
655 | 7 | |a Perspective Study |2 local | |
856 | 4 | 1 | |u https://doi.org/10.17352/2455-2968.000019 |z Connect to this object online. |